Medications

Study: Copanlisib + rituximab slows relapsed indolent lymphoma

Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...

Health

Scientist recommends ways to improve electronic health records

In an editorial in the Journal of General Internal Medicine, Regenstrief Institute research scientist Michael Weiner, MD, MPH highlights shortcomings of electronic health records (EHRs) in living up to their full potential, ...

Genetics

Can a genetic test predict if you will develop type 2 diabetes?

When I got home after work I was surprised to find my husband and three children sitting by the television and watching the news. They had just learned that the direct to consumer genetic testing company 23andMe was now offering ...

Arthritis & Rheumatism

To treat or not to treat (to target) in gout

Gout is the most common inflammatory arthritis worldwide, caused by high levels of uric acid in the blood. Deposits of uric acid crystals cause episodes of painful attacks in the joints and can accumulate in the skin as nodules. ...

page 3 from 5